RayKnowChina Research Map
Shortlist

Not yet recruitingLung cancerPancreatic cancerPhase 1

Registered title, quoted from ClinicalTrials.gov

HSK41959 With Standard Therapy in Solid Tumors With MTAP Deletion

An open trial on lung cancer and pancreatic cancer, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 1 hospital on this site is listed as study site.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Study siteShanghai East Hospital, Tongji University同济大学附属东方医院ShanghaiHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07699757, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 5

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (5 points)Hide the checklist
  1. 18 years to Not stated; sex: all

    Registered eligibility fields

  2. Histologically or cytologically confirmed advanced malignant tumor with MTAP deficiency identified by a validated assay.

    Inclusion criterion 4

  3. ECOG performance status of 0 to 1.

    Inclusion criterion 2

  4. Known actionable driver alterations or prior therapies excluded by the protocol for specific NSCLC cohorts (for example EGFR, ALK, ROS1, BRAF, NTRK, MET, RET, KRAS G12C, HER2, as applicable).

    Exclusion criterion 3

  5. At least one measurable lesion according to RECIST version 1.1.

    Inclusion criterion 5

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; earlier treatment; other conditions the trial excludes; pregnancy, breastfeeding and contraception.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07699757, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Adult participants aged 18 years or older.
  • ECOG performance status of 0 to 1.
  • Life expectancy of at least 3 months.
  • Histologically or cytologically confirmed advanced malignant tumor with MTAP deficiency identified by a validated assay.
  • At least one measurable lesion according to RECIST version 1.1.
  • For NSCLC cohorts: advanced or metastatic NSCLC meeting protocol-specified disease characteristics and prior treatment requirements.
  • For PDAC cohorts: advanced or metastatic PDAC meeting protocol-specified disease characteristics and prior treatment requirements.
  • Adequate bone marrow, hepatic, renal, and coagulation function.
  • Willingness to provide tumor tissue and/or undergo protocol-required biomarker testing, if applicable.

Exclusion Criteria:

  • Prior exposure to agents targeting the MAT2A or PRMT5 pathway.
  • Prior antitumor therapy or unresolved toxicities not meeting protocol-defined washout/recovery requirements.
  • Known actionable driver alterations or prior therapies excluded by the protocol for specific NSCLC cohorts (for example EGFR, ALK, ROS1, BRAF, NTRK, MET, RET, KRAS G12C, HER2, as applicable).
  • Significant gastrointestinal disorders that may affect drug absorption.
  • Clinically significant cardiovascular disease, including clinically relevant QTc prolongation, reduced left ventricular ejection fraction, or severe heart failure.
  • Uncontrolled metabolic disease, uncontrolled hypertension, or active infection.
  • Known HIV infection, active hepatitis B with significant viral replication, or active hepatitis C infection.
  • Use of prohibited concomitant medications, including strong inhibitors or inducers of CYP3A4, P-gp, BCRP, or other protocol-specified transporters/enzymes within the required washout period.
  • Other serious medical or psychiatric conditions that, in the investigator's judgment, would make study participation inappropriate.

Quoted from ClinicalTrials.gov, NCT07699757, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07699757, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07699757